Diaxonhit discovers and commercializes specialty diagnostic products in the areas of transplantation, infectious diseases, and cancer diagnosis. It offers Tetanus Quick Stick, a proprietary test that is used in emergency clinics for the evaluation of the protective status of a patient against tetanus. The company's in-house development products include the BJI InoPlex, a multiplex serological test used for the diagnosis of prosthetic joint infections; and Dx15, a test for the diagnosis of thyroid cancer. Its licensed products comprise AlloMap, a gene-expression profiling based blood test for regular and non-invasive surveillance of heart transplant recipients for acute cellular rejection. Diaxonhit was founded in 1997 and is headquartered in Paris, France.
diaxonhit (ALEHT:Euronext Paris)
65 Boulevard Masséna
Phone: 33 1 53 94 77 00
Fax: 33 1 53 94 77 07www.exonhit.com
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact DIAXONHIT, please visit www.exonhit.com. Company data is provided by Capital IQ. Please use this form to report any data issues.